To investigate whether change in BCR signaling occurs in CLL cells from patients on other therapies we performed kinome profiling on four patient samples from the IcICLLe clinical trial testing ibrutinib. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.